Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07588568 · ClinicalTrials.gov registry record · Phase 2
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Not yet
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT07588568 is a Phase 2 study that has not yet begun recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 52 participants.
The verdict
NCT07588568, a Phase 2 study, has not yet begun recruiting, sponsored by University of North Carolina, Chapel Hill.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib * Fill out surveys and answer health questions * Visit the clinic every 4 weeks for checkups and tests
Interventions
- DRUG Upadacitinib 30mg Dose
- OTHER Upadacitinib Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07588568
The ClinicalTrials.gov registry entry for NCT07588568 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Upadacitinib 30mg Dose is the first listed.
NCT07588568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07588568 about?
NCT07588568 is a clinical study titled "A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis". The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE). The main question it aims to answer are: \- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity? Participants will: * ...
What is the current status of trial NCT07588568?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2026-07. Estimated completion is 2030-06.
What interventions are being tested in trial NCT07588568?
The interventions under investigation include: Upadacitinib 30mg Dose (DRUG), Upadacitinib Matching Placebo (OTHER).
Who is sponsoring clinical trial NCT07588568?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.